Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Pituitary
Published in: Pituitary 4/2009

01-12-2009

Acromegaly: correlation between expression of somatostatin receptor subtypes and response to octreotide-lar treatment

Authors: Ana Paula M. Casarini, Raquel S. Jallad, Emília M. Pinto, Iberê C. Soares, Suely Nonogaki, Daniel Giannella-Neto, Nina R. Musolino, Venâncio A. F. Alves, Marcello D. Bronstein

Published in: Pituitary | Issue 4/2009

Login to get access

Abstract

About one-third of acromegalics are resistant to the clinically available somatostatin analogs (SA). The resistance is related to density reduction or different expression of somatostatin receptor subtypes (SSTR). This study analyzes SSTR’s expression in somatotrophinomas, comparing to SA response, hormonal levels, and tumor volume. We analyzed 39 somatotrophinomas; 49% were treated with SA. The most expressed SSTR was SSTR5, SSTR3, SSTR2, SSTR1, and SSTR4, respectively. SSTR1 and SSTR2 had higher expression in patients that had normalized GH and IGF-I. SSTR3 was more expressed in patients with tumor reduction. There was a positive correlation between the percentage of tumor reduction and SSTR1, SSTR2 and SSTR3 expression. Also, a positive correlation between SSTR2 mRNA expression and the immunohistochemical reactivity of SSTR2 was found. Our study confirmed the association between the SA response to GH and IGF-I and the SSTR2. Additionally, this finding was also demonstrated in relation to SSTR1.
Literature
1.
2.
3.
Schonbrunm A, Tashjian H Jr (1978) Characterization of functional receptors for somatostatin in rat pituitary cells in culture. J Biol Chem 253(18):6473–6483
4.
Reisine T, Bell G (1995) Molecular biology of somatostatin receptors. Endocr Rev 16:427–442PubMed
5.
6.
Taboada GF, Luque RM, Bastos W et al (2007) Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas. Eur J Endocrinol 156:65–74. doi:10.​1530/​eje.​1.​02313 CrossRefPubMed
7.
8.
Barlier A, Boullier LP, Gunz G et al (1999) Impact of gsp oncogene on expression of genes coding for Gsa, Pit-1, Gi2a, and somatostatin receptor 2 in human somatotroph adenomas: involvement in octreotide sensitivity. J Clin Endocrinol Metab 84:2759–2765. doi:10.​1210/​jc.​84.​8.​2759 CrossRefPubMed
9.
Danila DC, Haidar JNS, Zhang X et al (2001) Somatostatin receptor-specific analogs: effects on cell proliferation and growth hormone secretion in human somatotroph tumors. Clin Endocrinol Metab 86:2976–2981. doi:10.​1210/​jc.​86.​7.​2976 CrossRef
10.
11.
Greenman Y, Melmed S (1994) Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR5 expression in the mammosomatotroph lineage. J Clin Endocrinol Metab 79:724–729. doi:10.​1210/​jc.​79.​3.​724 CrossRefPubMed
12.
Teijeiro R, Rios R, Costoya J et al (2002) Activation of human somatostatin receptor 2 promotes apoptosis through a mechanism that is independent from induction of p53. Cell Physiol Biochem 12:31–38. doi:10.​1159/​000047824 CrossRefPubMed
13.
14.
15.
16.
Bronstein M, Musolino N, Jallad R et al (2005) Pharmacokinetic profile of lanreotide Autogel in patients with acromegaly after four deep subcutaneous injections of 60, 90 or 120 mg every 28 days. Clin Endocrinol (Oxf) 63:514–519. doi:10.​1111/​j.​1365-2265.​2005.​02372.​x CrossRef
17.
18.
19.
20.
21.
Saveanu A, Lavaque E, Gunz G et al (2002) Demonstration of enhanced potency of a chimeric somatostatin–dopamine molecule, BIM-23 A 387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenomas cells. J Clin Endocrinol Metab 87:5545–5552. doi:10.​1210/​jc.​2002-020934 CrossRefPubMed
22.
Saveanu A, Gunz G, Dufour H et al (2001) BIM-23244, a somatostatin receptor subtype 2 and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide—resistant human GH secreting adenomas. J Clin Endocrinol Metab 86:140–145. doi:10.​1210/​jc.​86.​1.​140 CrossRefPubMed
23.
Jallad RS, Musolino NR, Kodaira S et al (2007) Does partial surgical tumor removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue? Clin Endocrinol (Oxf) 67(2):310–315. doi:10.​1111/​j.​1365-2265.​2007.​02885.​x CrossRef
24.
Antonov J, Goldstein DR, Oberli A et al (2005) Reliable gene expression measurements from degraded RNA by quantitative real-time PCR depend on short amplicons and a proper normalization. Lab Invest 85(8):1040–1050. doi:10.​1038/​labinvest.​3700303 CrossRefPubMed
25.
Ponchel F, Toomes C, Bransfield K et al (2003) Real-time PCR based on SYBR-Green I fluorescence: an alternative to the TaqMan assay for a relative quantification of gene rearrangements, gene amplifications and micro gene deletions. BMC Biotechnol 13:3–18
26.
Jaquet P, Saveanu A, Gunz G et al (2000) Human somatostatin receptors subtypes in acromegaly: distinct patterns of menssenger ribonucleic acid expression and hormone suppression identify distinct tumoral phenotypes. J Clin Endocrinol Metab 85:781–792. doi:10.​1210/​jc.​85.​2.​781 CrossRefPubMed
27.
28.
29.
30.
31.
32.
Florio T, Thellung S, Corsaro A et al (2003) Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro. Clin Endocrinol (Oxf) 59:115–128. doi:10.​1046/​j.​1365-2265.​2003.​01811.​x CrossRef
33.
Hofland LJ, Hoek JVD, Koetsveld PMV et al (2004) The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone and prolactin secreting pituitary adenomas in vitro. J Clin Endocrinol Metab 89(4):1577–1585. doi:10.​1210/​jc.​2003-031344 CrossRefPubMed
34.
Park C, Yang I, Woo J et al (2004) Somatostatin (SRIF) receptor subtype 2 and 5 gene expression in growth hormone-secreting pituitary adenomas: the relationship with endogenous SRIF activity and response to Octreotide. Endocr J 51(2):227–236. doi:10.​1507/​endocrj.​51.​227 CrossRefPubMed
35.
36.
37.
Etxabe J, Gaztambide S, Latorre P et al (1993) Acromegaly: an epidemiological study. J Endocrinol Invest 16:181–187PubMed
38.
39.
40.
41.
42.
Jaquet P, Gunz G, Saveanu A et al (2005) Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy. Eur J Endocrinol 153:135–141. doi:10.​1530/​eje.​1.​01950 CrossRefPubMed
43.
44.
45.
46.
47.
Cozzi R, Attanasio R, Montini M et al (2003) Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? J Clin Endocrinol Metab 88:3090–3098. doi:10.​1210/​jc.​2003-030110 CrossRefPubMed
48.
Matrone C, Pivonello R, Colao A et al (2004) Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs. Neuroendocrinology 79:142–148. doi:10.​1159/​000077272 CrossRefPubMed
49.
Zatelli MC, Piccin D, Tagliati F et al (2003) Somatostatin receptor subtype 1 selective activation in human growth hormone (GH)- and prolactin (PRL)-secreting pituitary adenomas: effects on cell viability, GH and PRL secretion. J Clin Endocrinol Metab 88:2797–2802. doi:10.​1210/​jc.​2002-021825 CrossRefPubMed
50.
51.
Casarini AP, Pinto EM, Jallad RS et al (2006) Dissociation between tumor shrinkage and hormonal response during somatostatin analog treatment in an acromegalic patient: preferential expression of somatostatin receptor subtype 3. J Endocrinol Invest 29(9):826–830PubMed
52.
Resmini E, Dadati P, Ravetti JL et al (2007) Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting Octreotide in an acromegalic patient. J Clin Endocrinol Metab 92(5):1592–1599. doi:10.​1210/​jc.​2006-2084 CrossRefPubMed
Metadata
Title
Acromegaly: correlation between expression of somatostatin receptor subtypes and response to octreotide-lar treatment
Authors
Ana Paula M. Casarini
Raquel S. Jallad
Emília M. Pinto
Iberê C. Soares
Suely Nonogaki
Daniel Giannella-Neto
Nina R. Musolino
Venâncio A. F. Alves
Marcello D. Bronstein
Publication date
01-12-2009
Publisher
Springer US
Published in
Pituitary / Issue 4/2009
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-009-0175-1

Other articles of this Issue 4/2009

Pituitary 4/2009 Go to the issue

Letter

Pituicytoma and isolated ACTH deficiency

OriginalPaper

Utility of single luteinizing hormone determination 3 h after depot leuprolide in monitoring therapy of gonadotropin-dependent precocious puberty

OriginalPaper

Effects of physical training on serum and pituitary growth hormone contents in diabetic rats

OriginalPaper

Limited effects of growth hormone replacement in patients with GH deficiency during long-term cure of acromegaly

OriginalPaper

Effects of 5 years of growth hormone (GH) replacement therapy on cardiac parameters and physical performance in adults with GH deficiency

Letter

Confirmation of local amino acid sequence homology between human prolactin and the amyloid-related proteins
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits